Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

Fisker Stock Is a Strong Electric Vehicle Play for Patient Investors

By Thomas Niel, InvestorPlace Contributor

Yet, with the aforementioned foundation in place, coupled with the lessons it learned from the failure of its predecessor, consider FSR stock a worthwhile (but still risky) long-term EV play at today's prices.

All Bets are Off Whether FuboTV Stock Can Bounce Back

By Thomas Niel, InvestorPlace Contributor

Even with its recent strong growth numbers, it may not be enough to push FUBO stock back towards its high water mark.

With Better ‘Reopening’ Plays Out There, Hold off on Airbnb Stock

By Thomas Niel, InvestorPlace Contributor

Add in the end of the insider lockup, and it may tough for this recovery play to gain from here. With other kinds of travel stocks (like airlines) offering greater runway (if we see off-the-charts resurgence in travel later this year), it may be best to stick to them, and steer clear of ABNB stock.

Ankr Is Yet Another Altcoin to Consider Once Crypto Prices Stabilize

By Thomas Niel, InvestorPlace Contributor

While its long-term prospects remain strong, now's not the time to pounce on ANKR. With the risk of it falling again, taking your time seems to be the best move today.

Ocugen Stock Will Probably Drop Below $1

By Thomas Niel, InvestorPlace Contributor

Ocugen will only make money from sales of its vaccine in the United States, but by the time that's possible, it'll be too late.

Load More